Bicara Therapeutics 2026年季度报告

(Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _______________Commission file number 001-42271_________________________ BICARA THERAPEUTICS INC. (Exact name of registrant as specified in its charter)_________________________ Delaware83-2903745 (State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.) 116 Huntington Ave Suite 703 Boston,Massachusetts (Address of Principal Executive Offices)(Zip Code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesNo☒ As of August 6, 2026, the registrant had 66,172,934 shares of common stock, $0.0001 par value per share, outstanding. Item 1.Financial Statements (Unaudited) Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 Condensed Consolidated Statements ofOperations andComprehensive Loss for the Three and Six MonthsEnded June 30, 2026 and 2025 Condensed Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June 30,2026 and 2025 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2026 and 2025 Notes to Unaudited Condensed Consolidated Financial Statements Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3.Quantitative and Qualitative Disclosures About Market Risk Item 4.Controls and Procedures PART II:OTHER INFORMATION Item 1.Legal Proceedings Item 1A.Risk Factors Item 3.Defaults Upon Senior Securities Item 5.Other Information SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS We are subject to numerous risks and uncertainties, including those further described below in the section titled “Risk Factors” in thisQuarterly Report on Form 10-Q, that represent challenges that we face in connection with the successful implementation of ourstrategy and the growth of our business. In particular, the following considerations, among others, may offset our competitive strengthsor have a negative effect on our business strategy, which could materially adversely affect our business, financial conditions, results ofoperations, future growth prospects, or cause a decline in the price of our common stock: •We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluateour current business and predict our future success and viability. We have incurred significant financial losses since ourinception and anticipate that we will continue to incur significant financial losses for the foreseeable future. •If we are unable to raise capital when needed, or on acceptable terms, we may be unable to complete the development andcommercialization of ficerafusp alfa or any future product candidates.•Our business is highly dependent on the success of ficerafusp alfa. If we are unable to successfully complete clinicaldevelopment, obtain regulatory approval for or commercialize ficerafusp alfa, or if we experience delays in doing so, ourbusiness will be materially harmed.•We face significant competition from other biotechnology and pharmaceutical companies, and our operating results willsuffer if we fail to compete effectively.•Our business is dependent on our ability to advance ficerafusp alfa and future product candidates through clinical trials,obtain marketing approval and ultimately commercialize them.•Clinical development involves a le